PX3 Sleep
Research
Preliminary PX3 Clinical Sleep Trial Results
PX3, a fully customized Mandibular Advancement Device (MAD), is clinically validated to treat mild to moderate obstructive sleep apnea (OSA), and supported by numerous studies on MADs and oral appliance therapy for the effectiveness in treating mild to moderate OSA.
While CPAP therapy remains a top option for patients suffereing from OSA, PX3 offers a viable alternative for those unable to tolerate CPAP or seeking non-surgical or non-pharmalogical solutions.
PX3 is also an ideal solution for high-performers without an OSA diagnosis but facing sleep deprivation, high-pressure, and high-stress, aiming to improve their sleep quality and ability to perform.
​
Before deciding on any treatment options, it is imperative that you first consult with a qualified medical or dental professional. As with any treatment solution, there are certain limitations and potential risks that you need to discuss and consider with your healthcare provider.
43.52% decrease in apnea events
43.32% decrease in snoring
1.59% increase in blood oxygen levels
Supporting (MAD) studies
PX3 Performance Research
Physiological Effects of Wearing Athletic Mouth Pieces While Performing Various Exercises
Military Medicine, Volume 183, Issue suppl_1, March-April 2018, Pages 510–515,
Michael F Zupan, USAFA, BSC (Ret.), Dyana L Bullinger, MS, Brenda Buffington, EdD, Caroline Koch, BS, Samantha Parker, BS, Steve Fragleasso, BS, Taylor Fogg, Shay Rasmussen-Woerner, BS
Participants:
Twenty-five fully informed, non-smoking male and female subjects participated in this research study. The subject pool comprised non-smoking United States Air Force Academy (USAFA) cadets, USAFA civilian employees, and United States military members that were currently partaking in aerobic exercise for more than 30 min/d, at least three times per week.
13% increase in strength
9% increase in endurance
